Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients

In chronic hepatitis C (CHC), liver biopsy is the gold standard method for assessing liver histology, however it is invasive and can have complications. Non-invasive markers have been proposed and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) has been shown as an easy and inexpensi...

Full description

Saved in:
Bibliographic Details
Published in:The Brazilian journal of infectious diseases 2008-02, Vol.12 (1), p.15-19
Main Authors: Silva, Jr, Roberto Gomes da, Fakhouri, Ricardo, Nascimento, Tereza Virgínia Bezerra, Santos, Igor Martins, Barbosa, Luciana Mendonça Morais
Format: Article
Language:English
Subjects:
Adult
Aged
Alanine Transaminase - blood
Aspartate aminotransferase
Aspartate Aminotransferases - blood
Biomarkers - blood
Biopsy
Chronic hepatitis C
cirrhosis
Clinical Enzyme Tests
Complications and side effects
Diagnosis
Disease Progression
Drug therapy
Epidemiologic Methods
Female
fibrosis
Health aspects
Hepatitis C
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - pathology
Humans
INFECTIOUS DISEASES
liver biopsy
Liver cirrhosis
Liver Cirrhosis - diagnosis
Liver Cirrhosis - pathology
Male
Middle Aged
Platelet Count
Risk factors
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In chronic hepatitis C (CHC), liver biopsy is the gold standard method for assessing liver histology, however it is invasive and can have complications. Non-invasive markers have been proposed and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) has been shown as an easy and inexpensive marker of liver fibrosis. This study evaluated the diagnostic performance of APRI for significant fibrosis and cirrhosis prediction in CHC patients. This study included treatment-naive CHC patients who had undergone liver biopsy from January 2000 to August 2006. All histological slides were reviewed according to the METAVIR system. APRI was calculated based on laboratory results performed within four months from the biopsy. Twenty-eight (56%) patients had significant fibrosis (F2-F4) and 13 (26%) had cirrhosis (F4). The area under ROC curves of APRI for predicting significant fibrosis and cirrhosis were 0.92 (0.83-1.00) and 0.92 (0.85-1.00), respectively. Using cut-off values recommended by prior studies, significant fibrosis could be identified, in accordance with liver biopsy, in 44% and cirrhosis in 66% of patients. APRI could identify significant fibrosis and cirrhosis at a high degree of accuracy in studied patients.
ISSN:1413-8670
1678-4391
1678-4391
1413-8670
DOI:10.1590/S1413-86702008000100005